We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

40 hedge funds and large institutions have $22.3M invested in F-star Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% less capital invested

Capital invested by funds: $25M → $22.3M (-$2.68M)

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

20% less funds holding

Funds holding: 50 → 40 (-10)

90% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 10

Holders
40
Holders Change
-10
Holders Change %
-20%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
11
Reduced
13
Closed
10
Calls
$688K
Puts
–
Net Calls
+$688K
Net Calls Change
-$50K

Top Buyers

Rank Fund Capital Flow
1
HP
Hikari Power
Japan
+$410K
2
BI
BVF Inc
California
+$318K
3
JP Morgan Chase
JP Morgan Chase
New York
+$149K
4
MAM
Morse Asset Management
Connecticut
+$127K
5
TA
Tiedemann Advisors
New York
+$105K

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$605K
2
Millennium Management
Millennium Management
New York
-$466K
3
Goldman Sachs
Goldman Sachs
New York
-$363K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$230K
5
Deutsche Bank
Deutsche Bank
Germany
-$181K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAG
26
Crestwood Advisors Group
Massachusetts
$53K – – –
Bank of New York Mellon
27
Bank of New York Mellon
New York
$52K – – –
State Street
28
State Street
Massachusetts
$46K +$1.65K +100 +3%
AIM
29
Arcadia Investment Management
Michigan
$41K – – –
LP
30
LMR Partners
United Kingdom
$40K – – –
Acadian Asset Management
31
Acadian Asset Management
Massachusetts
$27K – – –
MAM
32
Meeder Asset Management
Ohio
$10K +$6.36K +386 +125%
Victory Capital Management
33
Victory Capital Management
Texas
$10K +$11.6K +703 New
UBS Group
34
UBS Group
Switzerland
$8K -$9.82K -596 -50%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$7K – – –
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$5.65K – – –
Citigroup
37
Citigroup
New York
$5K -$18K -1,093 -74%
Bank of America
38
Bank of America
North Carolina
$2K -$39.6K -2,405 -94%
GT
39
Glenmede Trust
Pennsylvania
$14 – – –
Goldman Sachs
40
Goldman Sachs
New York
– -$363K -24,627 Closed
Deutsche Bank
41
Deutsche Bank
Germany
– -$181K -11,000 -100%
FI
42
Fosun International
China
– -$122K -7,775 Closed
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
– -$91K -6,171 Closed
Barclays
44
Barclays
United Kingdom
– -$67K -4,539 Closed
Jane Street
45
Jane Street
New York
– -$59K -3,998 Closed
CS
46
Credit Suisse
Switzerland
– -$37K -2,557 Closed
TRCT
47
Tower Research Capital (TRC)
New York
– -$22K -1,507 Closed
Legal & General Group
48
Legal & General Group
United Kingdom
– -$9K -579 Closed
AWM
49
Arbor Wealth Management
Florida
– -$1K -75 Closed
1
2

FSTX Hedge Fund Activity: Q3 2019 in Review

40 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q3 2019, worth a combined $22.3M — down 11% from $25M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FSTX and 1 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 11 added.

The largest buyer was Hikari Power, adding an estimated $410K. The largest seller was Northern Trust, cutting an estimated $605K.

  • 40 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q3 2019, down from 50 in Q2 2019.
  • Funds reported $22.3M of F-star Therapeutics, Inc. Common Stock stock for Q3 2019, down 11% quarter-over-quarter.
  • 1 fund opened new F-star Therapeutics, Inc. Common Stock positions in Q3 2019 and 10 closed out, a net change of -9 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q3 2019 was Hikari Power, an estimated $410K added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q3 2019 was Northern Trust, an estimated $605K sold.

Based on aggregated 13F filings for Q3 2019.